II. Mechanism: Natural Glucocorticoids (e.g. Cortisol)
- See Adrenal Gland Physiology
- Pathway
- Adrenal Cortex synthesizes and releases 21-carbon steroids in response to ACTH or Angiotensin II
- Glucocorticoids bind and activate cell surface Glucocorticoid receptors
- Triggers translocation of the Ligand-receptor complex to the nucleus
- In the nucleus, Glucocorticoid-responsive genes (e.g. lipocortins) are expressed
- Inhibits Phospholipase A2
- Prevents Arachidonic Acid release from phospholipid membranes
- Blocks synthesis of inflammatory Prostaglandins and Leukotrienes
- Inhibits inflammatory Cytokines
- Interleukin-1 (IL-1)
- Interleukin-6 (IL-6)
- Cytotoxic T-Lymphocytes
- Inhibits Phospholipase A2
- Glucocorticoids mobilize available energy sources (Glucose, fats, Amino Acids)
- Increases Serum Glucose
- Stimulates liver Gluconeogenesis and glycogenolysis
- Decreases Insulin receptor binding
- Increases serum Fatty Acids by promoting lipolysis of adipose Triglyceride stores
- Promotes truncal Obesity
- Increases blood Amino Acids by breaking down Proteins (outside liver)
- Increases Serum Glucose
- Glucocorticoid effects vary by tissue type
- Within the liver, anabolic (synthesis) effects predominate
- Within Muscle, skin, fat and connective tissue, catabolic (molecular breakdown, energy utilization) effects predominate
- Antiinflammatory activity
- Inhibit Histamine release
- Inhibits Lymphocyte production (but increases Neutrophil Count)
- Stabilizes MacrophageLysosomes and Antigen Processing
- Decreases Antibody production
- Gastrointestinal effects
- Increases gastric acid production and pepsin secretion
- Thins gastrointestinal mucosa
- Fluids and Electrolyte effects
- Increases Sodium retention
- Increases Potassium excretion
- Decreases Calcium absorption
- Increases clearance free water
- Metabolic Alkalosis
- Hematologic effects and Immune Effects
- Increases Red Blood Cell production (erythropoesis)
III. Mechanism: Synthetic Glucocorticoids (Corticosteroid analogs)
- As with natural Glucocorticoids, synthetic analogs have anti-inflammatory and immunomodulating activity
- Corticosteroid analogs are similar in structure and function to the natural 21-carbon steroids
IV. Precautions
- Systemic Glucocorticoids have significant adverse effects (see below)
- Systemic Glucocorticoids have many established indications with significant efficacy
- Asthma Exacerbation
- COPD Exacerbation
- Stress Dose Steroids
- Cancer Chemotherapy
- Peritonsillar Abscess
- Bells Palsy
- Acute Gout (in those unable to take NSAIDs)
- Extensive Allergic Contact Dermatitis (>20% of body surface area such as Rhus Dermatitis)
- However, many systemic steroid uses are NOT recommended (esp. for Upper Respiratory Infection) due to evidence against
- Not recommended in Acute Bronchitis (aside from acute COPD or Asthma Exacerbation)
- Not recommended in mild to moderate Acute Pharyngitis (aside from Peritonsillar Abscess)
- Not recommended in Acute Sinusitis
- Not recommended in Allergic Rhinitis (use Inhaled Corticosteroids instead)
- Not recommended in Carpal Tunnel Syndrome (use Carpal Tunnel Corticosteroid Injection instead)
- Controversial in Lumbar Radiculopathy (mixed study results)
V. Dosing: Adult
- Betamethasone (Celestone) 0.5 to 0.9 mg IM/PO qd
- Cortisone (Cortone) 25-300 mg orally daily
-
Dexamethasone (Decadron)
- Antiinflammatory: 0.5-10 mg/day PO/IM/IV divided every 6-12 hours
- Dexamethasone has high oral Bioavailability (80%) with onset of action within 1-2 hours
-
Hydrocortisone (Cortef)
- See Stress Dose Steroid
- General
- Parenteral: 100 to 150 mg IV/IM q2-6 hours prn
- Oral: 20 to 240 mg/day PO in divided dosing
- Adrenal Insufficiency
- Adults: 100 mg IV every 8 hours (or Dexamethasone 4 mg IV)
- Children: 1 to 2 mg/kg IV every 8 hours
- Newborns: 12.5 mg IV
- Infants and young children: 25 mg IV
- School Aged Children: 50 mg IV
- Teens (same as adult dosing): 100 mg IV
-
Methylprednisolone
- Parenteral (Solu-Medrol) 10 to 125 mg IV/IM
- Oral (Medrol) 4 to 48 mg PO qd
-
Medrol Dose pack: tapers from 24 to 0 PO over 7 days
- Avoid Medrol dose pack (replace with Prednisone 30 mg orally daily for 5 to 6 days would have similar effect)
- Triamcinolone (Aristocort, Kenalog) 4 to 48 mg PO/IM daily
-
Prednisolone (Prelone) 5-60 mg PO/IV/IM orally daily
- Requires no first pass metabolism via the liver (unlike Prednisone)
-
Prednisone (Deltasone) 5-60 mg orally daily
- Requires first pass metabolism through the liver, but has 1:1 bioavailablity in most cases
- Consider Prednisolone in severe liver disease
-
Rayos (delayed release version of Prednisone)
- Marketed to reduce morning inflammation in Rheumatoid Arthritis
- Taken at 10 pm with intended release starting at 2 am
- Unlikely to add significant benefit for the cost (more than $200 for thirty 5 mg tabs)
- (2012) Prescr Lett 19(12): 69
VI. Dosing: Child
-
Methylprednisolone (Solu-Medrol)
- Dose: 1-2 mg/kg/dose PO/IV/IM q6h up to 125 mg/dose
-
Prednisolone (Prelone)
- Dose: 1-2 mg/kg/dose PO qd to bid up to 60 mg/day
- Maximum: 60 mg per day
- Preparations
- Syrup: 15 mg/5 ml
- Liquid: 5 mg/5 ml
-
Dexamethasone
- Dexamethasone has high oral Bioavailability (80%) with onset of action within 1-2 hours
- Asthma Exacerbation: 0.3 to 0.6 mg/kg/day up to 10-15 mg for 1-2 days
- Croup: 0.15 to 0.6 mg/kg once up to 10 mg
VII. Agents: Relative Glucocorticoid Potency (equivalent dosages)
- High potency
- Betamethasone 0.6 to 0.75 mg
- Dexamethasone 0.75 mg
- Medium potency
- Methylprednisolone 4 mg
- Triamcinolone 4 mg
- Prednisolone 5 mg
- Prednisone 5 mg
- Low potency
- Hydrocortisone 20 mg
- Cortisone 25 mg
VIII. Agents: Relative anti-inflammatory potency
- High anti-inflammatory potency
- Betamethasone 20-30
- Dexamethasone 20-30
- Medium anti-inflammatory potency
- Low anti-inflammatory potency
- Hydrocortisone 1
- Cortisone 0.8
IX. Agents: Relative Mineralocorticoid Potency
X. Agents: Half Life
- Long Half-Life (36-54 hours)
- Betamethasone
- Dexamethasone (36 to 54 hours)
- Medium Half-Life (18-36 hours)
- Methylprednisolone
- Prednisolone (~36 hours)
- Prednisone (~36 hours)
- Triamcinolone
- Short Half-Life (8-12 hours)
XI. Adverse Effects (typically with Long-term Corticosteroid use)
- See Precautions above
- See Prevention below
- Even short course Corticosteroids are associated with increased serious adverse effects
- Fracture (RR 1.9, NNH 140)
- Venous Thromboembolism (RR 3.3, NNH 454)
- Sepsis (RR 5.3, NNH 1250)
- Waljee (2017) BMJ 12:357 +PMID: 28404617 [PubMed]
- See Corticosteroid Associated Osteoporosis
- See Steroid-Induced Hyperglycemia
- Corticosteroid Myopathy
- Motor restlessness
- Sleep disturbance
- Hypertension
- Iatrogenic Diabetes Mellitus (or acute worsening of Diabetes Mellitus control including Diabetic Ketoacidosis)
- Hyperlipidemia
- Fluid retention
- Immune Suppression
-
Kaposi Sarcoma
- Associated with prolonged Immunosuppression on Corticosteroids
- Avascular Necrosis (e.g. Osteonecrosis of the hip)
- May occur even after single, short-term low dose course
- Dilisio (2014) Orthopedics 37(7):e631-6 +PMID: 24992058 [PubMed]
- Corticosteroid Induced Adrenal Insufficiency
- Hypothalamic-Pituitary-Adrenal (HPA) Axis suppression with high dose steroids for prolonged periods (esp. children)
- Typically does not occur if Prednisone 20 mg equivalent used <2-3 weeks
- Tapering is generally not required for shorter steroid courses (and raises total steroid dose)
- Medrol dose pack (6 days of Methylprednisolone) offers no benefit and adds extra cost
- Instead prescribe one dose for 5 to 6 days (e.g. Prednisone 30 to 40 mg orally daily for 6 days)
- Cardiovascular disease risk
- Psychiatric effects
- Includes depression, anxiety, mania, Psychosis, Delirium and Insomnia
- Typically occurs in first week of therapy and resolves within a week of stopping the Corticosteroid
- Most have mild to moderate symptoms but may be severe in up to 5% of cases
- Symptoms may also occur (uncommonly) with high potency Topical Corticosteroids, Intranasal Corticosteroids
- Incidence of psychiatric effects increases with dose
- Occurs in 1% of patients on Prednisone 40 mg orally daily or less
- Occurs in 5% of patients on Prednisone 40 mg to 80 mg orally daily or less
- Occurs in 18% of patients on Prednisone 80 mg orally daily or more
- References
- (2014) Presc Lett 21(12):69-70
XII. Management: Corticosteroid Tapering
- Background
- Indications
- Disease flare expected with short course (e.g. slow taper in Rhus Dermatitis)
- See specific conditions for these protocols
- Corticosteroid duration >3 weeks (or frequent steroid bursts)
- Risk of adrenal suppression if physiologic dose (>5 or 7.5 mg daily for >3 weeks) OR
- Frequent Corticosteroid bursts (3 or more in 6 months)
- Disease flare expected with short course (e.g. slow taper in Rhus Dermatitis)
- Protocol: Taper for Corticosteroid duration >3 weeks (or frequent steroid bursts)
- Reduce dose by 10-20% every 1 to 2 weeks (slower if on Corticosteroids for years)
- Consider ACTH Stimulation Test to confirm recovery of adrenal function before discontinuation
- Indications to slow taper
- Disease flare (e.g. COPD or PMR exacerbation)
- Adrenal Insufficiency signs of symptoms (e.g. Hypotension, myalgias, Fatigue)
- References
- (2022) Presc Lett 29(3): 13-4
XIII. Prevention: Corticosteroid complications
- See Corticosteroid Associated Osteoporosis
- See Steroid-Induced Hyperglycemia
- Avoid use when not truly indicated (e.g. Sinusitis, Acute Bronchitis, Pharyngitis)
- See Precautions above
- Even short course Corticosteroids (1 week) are associated with increased risk of Fractures, VTE and Sepsis
- (2017) Presc Lett 24(7)
- Waljee (2017) BMJ 357:j1415 +PMID:28404617 [PubMed]
XIV. Management: Corticosteroids Pearls
-
Dexamethasone is ideal for single dose
- Dexamethasone has high oral Bioavailability (80%) with onset of action within 1-2 hours
- Duration of action approaches 60 hours
- No mineracorticoid activity
- However, Dexamethasone suspension is not tolerated well by children (due to taste)
- In Emergency Department, IV formulation (10 mg/ml) is given orally in flavor, Ibuprofen or Acetaminophen
- At home, Dexamethasone tablets may be given, and crushed in apple sauce
-
Prednisone and Prednisolone may be used interchangeably
- Similar in cost, Half-Life and activity (antiinflammatory, mineralcorticoid)
- Give Prednisone or Prednisolone once daily (instead of split dosing)
- Once daily dosing has sufficient duration of activity
- Split daily dosing (with a night dose) increases adverse effects (e.g. Insomnia)
- Limit split dosing to those patients who have gastrointestinal side effects on daily dosing amounts
XV. References
- Olson (2020) Clinical Pharmacology, Medmaster, Miami, p. 155-6
- Swadron and Hope in Herbert (2018) EM:Rap 18(9):16-8
- Dvorin (2020) Am Fam Physician 101(2): 89-94 [PubMed]
- Lane (1998) Endocrinol Metab Clin North Am 27:465-83 [PubMed]